Summary
The pharmacokinetic characteristics of amrinone have been studied in six female marmosets following oral administration of 1, 12.5, 25, 50 and 75 mg.kg−1 and an intravenous dose of lmg.kg−1. The mean plasma AUG)0 ∞ was determined at each dose level; the values obtained were 2.5, 18.7, 33.9, 103 and 312 μ.h.ml−1 for the oral doses of 1. 12.5, 25, 50 and 75 mg.kg−1 respectively and 1.9 μ.h.ml−1 for the intravenous dose of lmg.kg−1 Mean maximum observed plasma concentrations were 0.6, 7.1, 11.7, 23.7 and 40.0 μg.ml−1 respectively following oral doses. Over the range 1 to 50 mg.kg0 ∞ the AUCooe was linear; at 75 mg.kg−1 the AUCo0 8 was disproportionately greater. Elimination appeared to be first order over the dose range 1 to 50 mg.kg−1 and the 11/2 in the marmoset was approximately 1 to 3 hours over this dose range. The plasma levels achieved arc discussed in relation to the observed effects on the platelet population in this species following chronic administration at high dose levels.
Similar content being viewed by others
References
Ward A., Brogden R.N., Heel R.C., Speight T.M., Avery G.S. (1983): Amrinone: a preliminary review of its pharmacological properties and therapeutic use. Drugs. 26.468–502.
Baker J.F.. Chalecki B.W., Benziger D.P., OMelia P.E., Clemens S.D., Edelson J. (1982): Metabolism of amrinone in animals. Drug Metab. Dispos., 10.168–172.
Park G.B., Kersher R.P., Angellotti J., Williams R.L., Benct Z.L., Edelson J. (1983): Oral bioavailability and intravenous pharmacokinetics of amrinone in humans. J. Pharm. Sci., 72. 817–819.
Edelson J. Park G.B., Angellotti J., Kershner R.P., Ryan J.J., McMaham F.G. ( 1983): Dose proportionality of amrinone. Clin. Pharmacol. Ther., 34.190–194.
Larijani G.E., Rocci M.L., Newham D.L., Wilson H. (1985): The pharmacokinetics of amrinone at three dose levels in the rabbit. Pharmacol. Commun. Res., 4, 176–177.
Padrini R., Miglioli P.A., Casiglia E., Piovan D., Ferrari M. (1982): Farmacocinetica sperimentale and clinica delTamrinone. Boll. Soc. Ital. Cardiol., 27. 103–106.
Kullberg M.P., Dorrbecker B., Lennon J., Rowe E., Edelson J. (1980): High performance liquid chromatographic analysis of amrinone and its N-acetyl derivative in plasma. Pharmacokinetics of amrinone in the dog. J. Chromatogr., 187. 264–270.
Bason C.T., Pattison A., Howells D.D., Mitcheson J., Bonner F.W. (1986): Platelet population profiles: significance of species variation and drug-induced changes. J. Appl. Toxicol., 6. 437–441.
Eason C.T., Pattison A., Howells D.D., Bonner F.W., Martin J.F. (1988): The effect of amrinone. cyclophosphamide and anti-platelet serum on platelet production in the Gunn rat. J. Appl. Toxicol., In Press.
Kinney E.L., Ballard J.O., Carlin B., Zells R. (1983): Amrinonemedicaled thrombocytopenia. Scand. J. Haematol., 31. 376–380.
Treadway G. (1985): Clinical safety of intravenous amrinone — a review. Am. J. Cardiol.. 56. 39B-40B.
Wilmshurst P.T., AI-Hasan S.A.F., Sample M.J., Hamblin A.S., Kioy P.G., Lucas G.F., Savidge G.F., Webb-Peploe M.M. (1984): The effects of amrinone on platelet count, survival and function in patients with congestive cardiac failure. Br. J. Clin. Pharmacol., 17. 317–324.
Brandt J.T., Miller L., Hermiller J., Unverferth D.V., Leier C.V. (1984): Effect of oral amrinone on platelet function and survival. Clin. Pharmacol. Ther.. 36. 260–264
Eason C.T., Parke D.V., Clark B., Smith D.A. (1982): The mechanism of hepatotoxicity of a chromone carboxylic acid (FPL 52757) in the dog. Xenobiotica. 12.155.
Clarke A.J., Clark B., Eason C.T., Parke. D.V. (1985): An assessment of a toxicological incident in a drug development program and its implications. Regul. Toxicol. Pharmacol., 5. 109–119.
Clark B., Smith D.A. (1984): Pharmacokinetics and toxicity testing. CRC Crit. Rev. Toxicol., 12. 343–385.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Eason, C.T., Usansky, J.I., Henry, G.P. et al. The relationship between the pharmacokinetics of amrinone in the marmoset and platelet effects. European Journal of Drug Metabolism and Pharmacokinetics 13, 129–133 (1988). https://doi.org/10.1007/BF03191314
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF03191314